The association between SGLT2 inhibitors and new-onset acute coronary syndrome in the elderly: a population-based longitudinal cohort study

Table 2 Incidence rate of acute coronary syndrome in study groups

	2: 1 sex, age, and index date matching		P value	PS matching		P value
	Non- SGLT2i	SGLT2i	P value	Non- SGLT2i	SGLT2i	P value
N	112712	56356		53200	53200
Follow up person months	2325847	1180118		1099285	1111867
New case	1408	670		646	624
Incidence rate^a(95% C.I.)	6.05(5.75–6.38)	5.68(5.26–6.12)		5.88(5.44–6.35)	5.61(5.19–6.07)
Crude Relative risk (95% C.I.)	Reference	0.94(0.86–1.03)	0.1763	Reference	0.96(0.86–1.07)	0.4110
Adjusted HR^a (95% C.I.)^b	Reference	0.95(0.87–1.05)	0.3218	Reference	0.96(0.86–1.07)	0.4111

SGLT2i Sodium-glucose cotransporter-2 inhibitor
^aIncidence rate, per 10,000 person-months
^b adjusted hazard ratio, the covariates including year of index, sex, age, co-morbidities, and medication at baseline
PS: propensity score

ISSN: 1758-5996